Situation: Sanofi's Lantus Cancer Scare Shows How Enormous Power Lies With Few Experts

06/30/2009
Research Reloaded: 

Cancer fears over Sanofi's drug Lantus seem premature and overdone, and the whole affair has shown how a few experts can really shake markets even if their beliefs aren't necessarily proven. Sanofi shares have rebounded a bit after falling on the news, but at $29.5 are still below recent $33 levels.

 

The cancer scare over Sanofi-Aventis' Lantus shows just how much power over a company's drug sales -- and its stock -- are now concentrated in the hands of a tiny number of experts. Sanofi CEO Chris Viehbacher came out of his corner swinging Monday, saying an article in Study of Diabetes journal Diabetologia that called for more research into a potential link between Lantus and cancer was "of poor quality." He also said that "quick and dirty" studies of the link were not the answer.

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Allowed HTML tags: <a> <em> <strong> <cite> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Lines and paragraphs break automatically.

More information about formatting options

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
1 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.